# EDGAR Filing Document

**Accession Number:** 0001773751
**File Stem:** 0000950170-25-108312
**Filing Date:** 2025-8
**Character Count:** 9450
**Document Hash:** 53fc78e2e0f91745c19059faca2f1a7f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-108312.hdr.sgml**: 20250813

**ACCESSION NUMBER**: 0000950170-25-108312

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250813

**DATE AS OF CHANGE**: 20250813

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Hims & Hers Health, Inc.
- **CENTRAL INDEX KEY:** 0001773751
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91087
- **FILM NUMBER:** 251213751

**BUSINESS ADDRESS:**
- **STREET 1:** 2269 CHESTNUT ST
- **STREET 2:** #523
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94123
- **BUSINESS PHONE:** 415-851-0195

**MAIL ADDRESS:**
- **STREET 1:** 2269 CHESTNUT ST
- **STREET 2:** #523
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94123

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Oaktree Acquisition Corp.
- **DATE OF NAME CHANGE:** 20190412
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dudum Andrew
- **CENTRAL INDEX KEY:** 0001837796

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 2269 CHESTNUT STREET, #523
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94123

### Attached PDF Documents

**Attachment 1:** `ck0000000000-ex99_a.pdf`

_No text found in this document._

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**Hims & Hers Health, Inc.**

*(Name of Issuer)*

**Class A common stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**433000106**

*(CUSIP Number)*

**Andrew Dudum**<br>2269 Chestnut Street, #523<br>San Francisco CA 94123<br>415-851-0195

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**08/07/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **433000106** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Andrew Dudum** | Name of reporting person<br>**Andrew Dudum** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**SC** | Source of funds (See Instructions)<br>**SC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**23820905.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**23820905.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**23820905.00** | Aggregate amount beneficially owned by each reporting person<br>**23820905.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**10.3%** | Percent of class represented by amount in Row (11)<br>**10.3%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** 1. Includes (i) 9,333,039 shares of Class A Common Stock held by trusts affiliated with the Reporting Person, (ii) 92,313 shares of Class A Common Stock held directly by the Reporting Person, (iii) 8,377,623 shares of Class V Common Stock held by trusts affiliated with the Reporting Person, (iv) 164,368 shares of Class A Common Stock underlying restricted stock units expected to settle within 60 days, (v) 5,643,186 shares of Class A Common Stock underlying stock options exercisable within 60 days of the date of this Schedule 13D held by the Reporting Person, (vi) 80,023 shares of Class A Common Stock underlying stock options that are not exercisable within 60 days of the date of this Schedule 13D, but which are subject to service-based vesting over a four-year period, with approximately 4,468 options vesting per month through April 2027, and (vii) 130,353 shares of Class A Common Stock underlying stock options that are not exercisable within 60 days of the date of this Schedule 13D, but which are subject to service-based vesting over a four-year period, with approximately 21,725 options vesting per month through March 2026.  Excludes 1,296,568 shares of Class A Common Stock underlying restricted stock units not expected to settle within 60 days.

2. All shares of Class V Common Stock will convert automatically into an equal number of shares of Class A Common Stock (i) upon any transfer of shares of Class V Common Stock, with limited exceptions and (ii) upon adoption of a resolution by the Board at any time on or after the one-year anniversary of the date that both trigger conditions, as such conditions are described in the Issuer's Certificate of Incorporation, dated as of January 20, 2021, are satisfied.

3. Percentage is calculated based on 231,873,143 shares of Class A Common Stock, which is the sum of (i) 217,641,958 shares of Class A Common Stock of the Issuer outstanding as of August 1, 2025, as reported by the Issuer in its Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on August 4, 2025, plus (ii) 8,377,623 shares of Class V Common Stock of the Issuer outstanding, (iii) 164,368 shares of Class A Common Stock underlying restricted stock units expected to settle within 60 days, (iv) 5,643,186 shares of Class A Common Stock underlying stock options held by the Reporting Person that are exercisable within 60 days of the date of this Schedule 13D, and (v) 210,376 shares of Class A Common Stock underlying stock options held by the Reporting Person that are not exercisable within 60 days of the date of this Schedule 13D. The Reporting Person beneficially owns 10.3% of the outstanding shares of Class A Common Stock (assuming exercise of all outstanding stock options and conversion of all outstanding shares of Class V held by the Reporting Person) and 100% of the outstanding Class V Common Stock.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Class A common stock, $0.0001 par value per share

**(b) Name of Issuer:**
Hims & Hers Health, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
2269 Chestnut Street, #523, San Francisco, CA, 94123

This Amendment No. 3 to Schedule 13D relates to the Class A Common Stock, $0.0001 par value per share (Class A Common Stock) of Hims & Hers Health, Inc. (Issuer), and amends and supplements the initial statement on Schedule 13D filed by the Reporting Person with the Commission on February 1, 2021, as amended by Amendment No. 1 filed with the Commission on December 15, 2021 and Amendment No. 2 filed with the Commission on October 25, 2024 (collectively, the Original Schedule 13D and, as so amended and supplemented, the Statement). This Statement is being filed by the Reporting Person. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 3 have the meanings ascribed to them in the Original Schedule 13D.

**Item 4. Purpose of Transaction**

The information set forth in Item 4 of the Original Schedule 13D is incorporated herein by reference.

**Item 5. Interest in Securities of the Issuer**

**(a)**
See Items 7-11 of the cover pages of this Amendment No. 1.

**(b)**
See Items 7-11 of the cover pages of this Amendment No. 1.

**(c)**
The transactions in the securities of the Issuer by the Reporting Person since the sixtieth day prior to the date of the event requiring the filing of this Amendment No. 3 are set forth in Schedule A hereto and are incorporated herein by reference.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set forth in Item 6 of the Original Schedule 13D is incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Andrew Dudum

**Signature:** /s/ Alexandra Cotter Wilkins, as Attorney-in-Fact for Andrew Dudum

**Name/Title:** Andrew Dudum

**Date:** 08/13/2025